Purchase Order HHSN269201700325PC
- Not listed
- This federal contract award, with an ID of 75N90018K00052, was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a for-profit limited liability company. The $82,281.25 firm fixed-price purchase order is for medical laboratory testing services, primarily to support research and clinical programs at the NIH. Genedx, a wholly-owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic services to the federal government. This...
- This firm fixed-price purchase order was awarded by the Office of the Chief Operating Officer (a civilian agency), a component of the National Institutes of Health (NIH), to Genedx, LLC, a for-profit limited liability company. The $81,666 contract is for medical laboratory testing services, specifically genetic testing and diagnostic services. Genedx, a wholly owned subsidiary of Opko Health, Inc., provides comprehensive genetic testing, including mutation analysis, exome and genome...
- This federal contract award is for medical laboratory testing services and was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a leading provider of genetic testing and diagnostic services. The contract, valued at $81,410.00, is a firm fixed-price purchase order without a set-aside designation, indicating Genedx competed in the open market. Genedx operates from its facilities in Maryland and has held several Indefinite Delivery Vehicle (IDV) contracts with the...
- This federal contract award, valued at $89,127.00, was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a for-profit limited liability company and provider of genetic testing and diagnostic services. The contract is for medical laboratory testing services, primarily supporting research and clinical programs at the NIH. Genedx holds two significant Indefinite Delivery Vehicle (IDV) contracts with the NIH Clinical Center, one of which was set aside for small...
- This federal contract award is for medical laboratory testing services provided by Genedx, LLC to the National Institutes of Health (NIH) Clinical Center. The contract, valued at $100,000.00, is a firm fixed-price purchase order with an ultimate completion date of August 12, 2015. Genedx, a for-profit limited liability company, has been a provider of genetic testing services to the NIH, supporting various research and clinical programs, particularly at the NIH Clinical Center and the National...
- This is a firm fixed-price purchase order contract awarded by the Office of the Chief Operating Officer at the National Institutes of Health (NIH) to Genedx, LLC, a for-profit limited liability company, for medical laboratory testing services. The contract award, valued at $97,833.65, has a performance period from January 14, 2016, to an ultimate completion date of the same day. Genedx, a wholly owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic...
- This federal contract award to Genedx, LLC, doing business as Genedx, supports genetic mutation testing for the National Institutes of Health (NIH) Clinical Center. The $80,477.50 firm fixed-price purchase order has a performance period from July 2018 to July 2018. Genedx, a wholly owned subsidiary of Opko Health, Inc., is a leading provider of genetic testing and diagnostic services, specializing in comprehensive genetic analysis including mutation analysis, exome and genome sequencing, gene...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a leading provider of genetic testing and diagnostic services. The contract, valued at $75,395.00, provides for a range of genetic testing services to support NIH research and clinical programs, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. Genedx, a wholly owned subsidiary of Opko Health, Inc., has extensive...
- This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Human Genome Research Institute to Genedx, LLC, a subsidiary of Opko Health, Inc. The $25,000.00 firm fixed-price purchase order is for the provision of genetic testing services, including mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. The contract has a completion date of June 30, 2025. Genedx is the prime...
- This is a firm fixed-price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Genedx, LLC, a wholly owned subsidiary of Opko Health, Inc. The contract provides laboratory testing services, including genetic testing and diagnostic services, to support research and clinical programs at the NIH. The contract has a ceiling value of $5,775 and a period of performance through May 22, 2023. The contract was awarded on...
This federal contract award, with ID HHSN269201700325PC, was issued by the National Institutes of Health (NIH) Clinical Center to Genedx, LLC, a for-profit limited liability company. The contract is for $95,385.00 and is for medical laboratory testing services, specifically supporting genetic testing and analysis. The contract is a firm fixed-price purchase order without a set-aside designation, indicating Genedx competed in the open market for this award. Genedx, as a wholly owned subsidiary of Opko Health, Inc., has extensive experience providing genetic testing services to support NIH's research and clinical programs. This includes mutation analysis, exome and genome sequencing, gene panel testing, and mitochondrial testing. The contract allows the NIH Clinical Center to access Genedx's specialized testing capabilities on an as-needed basis, supporting ongoing research and patient care initiatives. In addition to this contract, Genedx holds two significant Indefinite Delivery Vehicles (IDVs) with the NIH Clinical Center for mutation analysis services, with ceiling values of $1,012,384 and $250,000, further demonstrating the company's role in supporting the agency's genetic research and clinical initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $95.4k | 10/16/17 |